Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis a vaccine 50 u/ml - suspension for injection - 50 u/ml - active: hepatitis a vaccine 50 u/ml excipient: aluminium as amorphous aluminium hydroxyphosphate sulphate borax sodium chloride water for injection - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus. primary immunisation should be given at least 2 weeks prior to expected exposure to hav. vaccination is recommended in children 12 months of age and older, adolescents, and adults who are at risk of contracting or spreading infection or who are at risk of life-threatening disease if infected, including but not limited to: · travellers to endemic or outbreak areas · frequently affected communities - members residing in any community with one or more recorded outbreaks within the last five years · daycare - children and staff of daycare centres as well as their parents, siblings, and other contacts · military personnel prior to departure for endemic or outbreak areas · persons for whom hepatitis a is an occupational hazard - health-care workers - staff and residents of orphanages, chronic care hospitals and mental health care facilities - sewage workers · haemophiliacs and other recipients of therapeutic blood products · persons who test positive for hepatitis c virus and have diagnosed liver disease · food handlers · consumers of high-risk foods e.g. raw shellfish · persons at increased risk of the disease due to their sexual practices - homosexually-active males - persons who repeatedly contract sexually transmitted diseases · human immunodeficiency virus (hiv)-infected adults · users of illicit injectable drugs vaqta will not prevent hepatitis caused by infectious agents other than hepatitis a virus.

Singapūra - angļu - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid - injection - 30 iu/0.5 ml

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (unii: qsn5xo8zsu) (bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde in - infanrix is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the 7th birthday). severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, or pertussis-containing vaccine, or to any component of infanrix is a contraindication [see description (11)] . because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with any of these components should be given. alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is being considered. encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including in

Armēnija - angļu - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin - suspenion for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose

Īrija - angļu - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - corynebacterium diphtheriae crm197 carrier protein aluminium phosphate - solution for injection - 0.5 millilitre

Izraēla - angļu - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin (prn or 69 kda omp); pertussis toxoid (pt); tetanus toxoid - suspension for injection - diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid (pt) 8 mcg / 0.5 ml; pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml - tetanus toxoid, combinations with diphtheria toxoid - tetanus toxoid, combinations with diphtheria toxoid - for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards.the administration of boostrix should be based on official recommendations

Singapūra - angļu - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - purified capsular polysaccharide of hib - injection, powder, for solution - 10mcg/0.5ml - purified capsular polysaccharide of hib 10mcg/0.5ml

Izraēla - angļu - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - measles virus enders edmonston strain (live, attenuated); mumps virus jeryl lynn™ (level b) strain (live, attenuated); rubella virus wistar ra 27/3 strain (live, attenuated); varicella virus oka/merck strain (live, attenuated) - powder and solvent for suspension for injection - measles virus enders edmonston strain (live, attenuated); varicella virus oka/merck strain (live, attenuated); rubella virus wistar ra 27/3 strain (live, attenuated); mumps virus jeryl lynn™ (level b) strain (live, attenuated) - measles, combinations with mumps, rubella and varicella, live attenuated - proquad is indicated for simultaneous vaccination against measles, mumps, rubella, and varicella in individuals from 12 months of age to 12 years of age.proquad can be administered to individuals from 9 months of age under special circumstances: outbreak situations, or travel to a region with high prevalence of measles.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - haemophilus influenzae type b prp 5ug (conjugated with 12.5 mcg tetanus toxoid);  ; neisseria meningitidis group c polysaccharide 5ug (5 mcg men c polysaccharide conjugated to 5 mcg tetanus toxoid) - injection with diluent - 0.5 ml - active: haemophilus influenzae type b prp 5ug (conjugated with 12.5 mcg tetanus toxoid)   neisseria meningitidis group c polysaccharide 5ug (5 mcg men c polysaccharide conjugated to 5 mcg tetanus toxoid) excipient: sodium chloride sucrose tetanus toxoid trometamol hydrochloride sodium chloride water for injection - menitorix is indicated for the prevention of invasive diseases caused by haemophilus influenzae type b (hib) and neisseria meningitidis serogroup c (menc).

Singapūra - angļu - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid (d) - injection - min 30iu/0.5ml